Leukemia & Lymphoma, Volume 62, Issue 6 (2021)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 62, Issue 6 (2021)

See all volumes and issues
Vol 65, 2024 Vol 64, 2023 Vol 63, 2022 Volume 62, 2021 Vol 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Vol 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentaries

Article Commentary
Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma
Xiaosheng Fang & Ken H. Young
Pages: 1281-1283
Published online: 02 Mar 2021
First Page PreviewforHepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma | Full Text | References | PDF (557.1 KB) | EPUB
  • 108 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections
Alain Mina, Sara Small & Leonidas C. Platanias
Pages: 1284-1286
Published online: 17 Mar 2021
First Page PreviewforConvalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections | Full Text | References | PDF (304.4 KB) | EPUB
  • 140 Views
  • 1 CrossRef citations
  • 0Altmetric
Article Commentary
Are phase III trials still important for FDA drug approval?
Mary-Elizabeth M. Percival & Elihu H. Estey
Pages: 1287-1288
Published online: 10 Mar 2021
CitationforAre phase III trials still important for FDA drug approval? | Full Text | References | PDF (351.4 KB) | EPUB
  • 96 Views
  • 1 CrossRef citations
  • 0Altmetric

Reviews

Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia
Paul J. Hampel, Sameer A. Parikh & Timothy G. Call
Pages: 1289-1301
Published online: 07 Jan 2021
AbstractforIncorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia | Full Text | References | PDF (1.4 MB) | EPUB
  • 318 Views
  • 1 CrossRef citations
  • 0Altmetric
Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma
Hua-Jay J. Cherng & Jason Westin
Pages: 1302-1312
Published online: 06 Jan 2021
AbstractforWhy R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma | Full Text | References | PDF (1.2 MB) | EPUB
  • 602 Views
  • 3 CrossRef citations
  • 0Altmetric

Original Articles

Article
The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT
Rebeca Lopez-Alonso, Shunan Qi, Tanya Mashiach, Michal Weiler-Sagie, Joachim Yahalom & Eldad J. Dann
Pages: 1313-1324
Published online: 22 Jan 2021
AbstractforThe presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 195 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma
Ravi K. Goyal, Preetesh Jain, Saurabh P. Nagar, Hannah Le, Shaum M. Kabadi, Keith Davis, James A. Kaye, Xianglin L. Du & Michael Wang
Pages: 1325-1334
Published online: 08 May 2021
AbstractforReal-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma | Full Text | References | PDF (2.1 MB) | EPUB | Supplemental
  • 555 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients
Shunfeng Hu, Na Chen, Kang Lu, Changqing Zhen, Xiaohui Sui, Xiaosheng Fang, Ying Li, Yingshu Luo, Xiangxiang Zhou & Xin Wang
Pages: 1335-1343
Published online: 05 Jan 2021
AbstractforThe prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 208 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis
Agrima Mian, Wei Wei, Allison M. Winter, Jack Khouri, Deepa Jagadeesh, Faiz Anwer, Aaron T. Gerds, Robert M. Dean, Ronald Sobecks, Brad Pohlman, Betty K. Hamilton, Navneet S. Majhail & Brian T. Hill
Pages: 1344-1352
Published online: 29 Dec 2020
AbstractforOutcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis | Full Text | References | PDF (1.6 MB) | EPUB
  • 727 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab
Roger M. Lyons, Mikhail Shtivelband, Edwin Kingsley, Mehdi Moezi, Donald Richards, Jeff Sharman, Xiaoshu Feng, Megan Cannan, Rafik Fellague-Chebra & Thomas E. Boyd
Pages: 1353-1360
Published online: 15 Jan 2021
AbstractforEfficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab | Full Text | References | PDF (776.9 KB) | EPUB | Supplemental
  • 247 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy
Alexander Augustyn, L. Jeffrey Medeiros, Ethan B. Ludmir, Jillian Gunther, Penny Fang, Shaoying Li, Chi Young Ok, Mikaela E. Bankston, Vivek Verma, Dario Pasalic, Sairah Ahmed, Loretta J. Nastoupil, Jason R. Westin, Paolo Strati, Sattva S. Neelapu, Ranjit Nair, Raphael E. Steiner, Swaminathan P. Iyer, Alma Rodriguez, Luis E. Fayad, Christopher R. Flowers, Bouthaina S. Dabaja & Chelsea C. Pinnix
Pages: 1361-1369
Published online: 22 Jan 2021
AbstractforThe impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy | Full Text | References | PDF (1.7 MB) | EPUB
  • 401 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis
Kelly M. Trevino, Peter Martin, Rebecca Saracino & John P. Leonard
Pages: 1370-1378
Published online: 04 Jun 2021
AbstractforUnmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis | Full Text | References | PDF (780.5 KB) | EPUB
  • 117 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Point-of-care ultrasound with handheld devices in hematology: a monocentric single-stage phase II study
Simona Pagliuca, Cecile Bailly, Alexis Talbot, Rémi Bertinchamp, Olivier Peyrony, Arben Elezi, Pierre Bourrier & Etienne Lengline
Pages: 1379-1385
Published online: 08 Jan 2021
AbstractforPoint-of-care ultrasound with handheld devices in hematology: a monocentric single-stage phase II study | Full Text | References | PDF (1 MB) | EPUB
  • 112 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019
Ghulam Rehman Mohyuddin, Kelly Koehn, Leyla Shune, Muhammad Aziz, Al-Ola Abdallah, Brian McClune, Siddhartha Ganguly, Joseph McGuirk & Suman Kambhampati
Pages: 1386-1395
Published online: 08 Jan 2021
AbstractforRenal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019 | Full Text | References | PDF (1.2 MB) | EPUB | Supplemental
  • 681 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience
Nadjoua Maouche, Bhuvan Kishore, Matthew W. Jenner, Kevin Boyd, Zara Bhatti, Sarah Anne Bird, Gurvin Chander, Rebecca Robinson, Grant D. Vallance, Mark Offer, Jaimal Kothari, Andy Peniket, Robin Aitchison, Moez Dungarwalla, Freya Collings, Ceri Bygrave & Karthik Ramasamy
Pages: 1396-1404
Published online: 25 Dec 2020
AbstractforIxazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience | Full Text | References | PDF (1,011.3 KB) | EPUB
  • 308 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma
Tomiyuki Sugi, Yasuo Nishigami, Hirohisa Saigo, Homare Hanai, Keisuke Takabatake, Mitsuo Mita, Shin Ohara, Shiro Ide, Tomoyuki Uchida, Morihiro Inoue & Masao Hagihara
Pages: 1405-1410
Published online: 28 Jan 2021
AbstractforAnalysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma | Full Text | References | PDF (599.3 KB) | EPUB
  • 419 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Eytan M. Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, Sherry Shi, Annie Guerin, Eric Q. Wu, Islam Sadek & Xiting Cao
Pages: 1411-1421
Published online: 11 Jan 2021
AbstractforTreatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 682 Views
  • 4 CrossRef citations
  • 0Altmetric
Article
KLF4 inhibition by Kenpaullone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent
Mayra Montecillo-Aguado, Mario Morales-Martínez, Sara Huerta-Yepez & Mario I. Vega
Pages: 1422-1431
Published online: 07 Jan 2021
AbstractforKLF4 inhibition by Kenpaullone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent | Full Text | References | PDF (1.9 MB) | EPUB
  • 289 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis
Jan M. Middeke, Raphael Teipel, Christoph Röllig, Sebastian Stasik, Armin Zebisch, Heinz Sill, Michael Kramer, Sebastian Scholl, Andreas Hochhaus, Edgar Jost, Tim H. Brümmendorf, Ralph Naumann, Björn Steffen, Hubert Serve, Heidi Altmann, Volker Kunzmann, Hermann Einsele, Stefani Parmentier, Markus Schaich, Andreas Burchert, Andreas Neubauer, Christoph Schliemann, Wolfgang E. Berdel, Katja Sockel, Friedrich Stölzel, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede & for the Study Alliance Leukemia (SAL)
Pages: 1432-1440
Published online: 05 Jan 2021
AbstractforDecitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis | Full Text | References | PDF (1.1 MB) | EPUB | Supplemental
  • 400 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
Eric Huselton, Michael P. Rettig, Theresa Fletcher, Julie Ritchey, Leah Gehrs, Kyle McFarland, Stephanie Christ, William C. Eades, Kathryn Trinkaus, Rizwan Romee, Shashikant Kulkarni, Armin Ghobadi, Camille Abboud, Amanda F. Cashen, Keith Stockerl-Goldstein, Geoffrey L. Uy, Ravi Vij, Peter Westervelt, John F. DiPersio & Mark A. Schroeder
Pages: 1441-1449
Published online: 19 Jan 2021
AbstractforA phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes | Full Text | References | PDF (1.4 MB) | EPUB
  • 340 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia
Jiasheng Wang, Marcos de Lima, Brenda W. Cooper, Kirsten Boughan, Leland Metheny, Folashade Otegbeye, Paolo F. Caimi, Molly Gallogly, Ehsan Malek, Shufen Cao, Pingfu Fu, Brett Glotzbecker, Nicholas K. Schiltz & Benjamin K. Tomlinson
Pages: 1450-1457
Published online: 18 Jan 2021
AbstractforEfficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia | Full Text | References | PDF (961.3 KB) | EPUB
  • 243 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension
Nauman A. Khan, Keerat A. Ahuja, Xiaofeng Wang & Neal F. Chaisson
Pages: 1458-1465
Published online: 25 Jan 2021
AbstractforEvaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension | Full Text | References | PDF (727.6 KB) | EPUB
  • 111 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia
Diana Abbott, Evan Cherry, Maria Amaya, Christine McMahon, Marc Schwartz, Amanda Winters, Jeffrey Schowinsky, Craig T. Jordan, Clayton Smith, Jonathan A. Gutman & Daniel A. Pollyea
Pages: 1466-1473
Published online: 30 Dec 2020
AbstractforThe propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 431 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study
Aubrey K. Hubbard, Michaela Richardson, Michelle A. Rosesler, Adina Cioc, Phuong L. Nguyen, Erica Warlick & Jenny N. Poynter
Pages: 1474-1481
Published online: 08 Jan 2021
AbstractforThe association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study | Full Text | References | PDF (722.3 KB) | EPUB
  • 155 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation
Ashvind Prabahran, Rachel Koldej, Lynette Chee, Eric Wong & David Ritchie
Pages: 1482-1489
Published online: 31 Jan 2021
AbstractforEvaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation | Full Text | References | PDF (799.7 KB) | EPUB
  • 294 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies
Silvia Ferrari, Chiara Caprioli, Alessandra Weber, Alessandro Rambaldi & Federico Lussana
Pages: 1490-1496
Published online: 18 Jan 2021
AbstractforConvalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies | Full Text | References | PDF (1.2 MB) | EPUB
  • 2794 Views
  • 25 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah’s Witnesses
Peter A. Riedell, Meng Wu, Jennifer M. Collins, Jacklyn M. Gideon, Andrzej J. Jakubowiak, Justin P. Kline, Satyajit Kosuri, Hongtao Liu, Sonali M. Smith & Michael R. Bishop
Pages: 1497-1501
Published online: 03 Feb 2021
First Page PreviewforBloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah’s Witnesses | Full Text | References | PDF (706.4 KB) | EPUB
  • 708 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter
Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy
Alexis Genthon, Thibault Chiarabini, Pierre Baylac, Nadia Valin, Tomas Urbina, Jérome Pacanowski, Arsène Mekinian, Eolia Brissot, Fella M.’Hammedi-Bouzina, Simona Lapusan, Mohamad Mohty, Karine Lacombe & Patrick Ingiliz
Pages: 1502-1505
Published online: 08 Jan 2021
First Page PreviewforSevere COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy | Full Text | References | PDF (548.9 KB) | EPUB
  • 2196 Views
  • 9 CrossRef citations
  • 0Altmetric
Letter
STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms
Shiqiang Qu, Yujiao Jia, Huijun Wang, Xiaofei Ai, Zefeng Xu, Tiejun Qin, Lijuan Pan, Bing Li, Gang Huang, Robert Peter Gale & Zhijian Xiao
Pages: 1506-1509
Published online: 07 Jan 2021
First Page PreviewforSTAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms | Full Text | References | PDF (1.1 MB) | EPUB | Supplemental
  • 309 Views
  • 3 CrossRef citations
  • 0Altmetric
Letter
Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML
Abdullah Ladha, Gavin Hui, Edna Cheung, Caroline Berube, Steven E. Coutre, Jason Gotlib, Michaela Liedtke, Tian Y. Zhang, Lori Muffly & Gabriel N. Mannis
Pages: 1510-1513
Published online: 24 Jan 2021
First Page PreviewforRoutine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML | Full Text | References | PDF (475.8 KB) | EPUB
  • 236 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country
Jayastu Senapati, Rishi Dhawan, Mukul Aggarwal, Pradeep Kumar, Ganesh Kumar Vishwanathan, Jasmita Dass, Seema Tyagi, Manoranjan Mahapatra & Tulika Seth
Pages: 1514-1517
Published online: 15 Jan 2021
First Page PreviewforVenetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country | Full Text | References | PDF (474 KB) | EPUB
  • 367 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical
Ankita Shahi, Gerald E. Weiss, Saswati Bhattacharya, Dana C. Baiu, Roberta Marino, Taner Pula, Natalie S. Callander, Fotis Asimakopoulos & Mario Otto
Pages: 1518-1521
Published online: 27 Jan 2021
First Page PreviewforTargeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical | Full Text | References | PDF (699 KB) | EPUB | Supplemental
  • 190 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies
Samer Al Hadidi & Carlos Almeida Ramos
Pages: 1522-1524
Published online: 24 Jan 2021
First Page PreviewforLevel of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies | Full Text | References | PDF (368.6 KB) | EPUB
  • 151 Views
  • 3 CrossRef citations
  • 0Altmetric
Letter
Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series
Alejandro Garcia-Horton, Dawn Maze, Caroline J. McNamara, Hassan Sibai, Vikas Gupta & Tracy Murphy
Pages: 1525-1527
Published online: 15 Jan 2021
First Page PreviewforAzacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series | Full Text | References | PDF (410.7 KB) | EPUB
  • 477 Views
  • 2 CrossRef citations
  • 0Altmetric
Letter
BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib
Esther Sathya Bama Benjamin, Niveditha Ravindra, Bharathi Murugan Rajamani, Senthamizhselvi Anandan, Bagavathi Kausalya, Vidya Veldore, Vikram Mathews, Shaji Ramachandran Velayudhan & Poonkuzhali Balasubramanian
Pages: 1528-1531
Published online: 22 Jan 2021
First Page PreviewforBCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib | Full Text | References | PDF (907.4 KB) | EPUB | Supplemental
  • 274 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)
Michael J. Hochman, Megan Othus, Roland B. Walter, Carole Shaw, Kelda Gardner, Mary-Elizabeth M. Percival, Anna B. Halpern, Paul C. Hendrie, Brenda M. Sandmaier & Elihu H. Estey
Pages: 1532-1535
Published online: 22 Mar 2021
First Page PreviewforEffect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML) | Full Text | References | PDF (792.9 KB) | EPUB | Supplemental
  • 245 Views
  • 3 CrossRef citations
  • 0Altmetric

Correspondences

Vincristine must NEVER be prepared or administered in a syringe
Peter Jeffrey Gilbar
Pages: 1536-1537
Published online: 22 Dec 2020
CitationforVincristine must NEVER be prepared or administered in a syringe | Full Text | References | PDF (341.6 KB) | EPUB
  • 165 Views
  • 0 CrossRef citations
  • 0Altmetric
Acute promyelocytic leukemia: if you wait it is too late
Emanuele Ammatuna & Jaap van Doesum
Page: 1538
Published online: 06 Jan 2021
CitationforAcute promyelocytic leukemia: if you wait it is too late | Full Text | References | PDF (175.3 KB) | EPUB
  • 124 Views
  • 0 CrossRef citations
  • 0Altmetric
Anemia and red blood cell abnormalities in COVID-19
Philip Murphy, Siobhan Glavey & John Quinn
Page: 1539
Published online: 22 Jan 2021
CitationforAnemia and red blood cell abnormalities in COVID-19 | Full Text | References | PDF (175.1 KB) | EPUB
  • 3879 Views
  • 3 CrossRef citations
  • 0Altmetric

Explore articles